Key Development The decision to end a long-standing research collaboration between GSK and Alector marks more than the conclusion of... Read more
Tag: #Global Trends
FROM DAILY TO WEEKLY: NOVO NORDISK’S AWIQLI COULD RESHAPE DIABETES CARE IN THE WORLD’S LARGEST INSULIN OPPORTUNITY
Key Development Novo Nordisk has launched Awiqli (insulin icodec) in India, making the country one of the earliest markets to... Read more
ASTRAZENECA AND DAIICHI SANKYO NEAR UK PRICING DEAL FOR ENHERTU: A TURNING POINT FOR CANCER DRUG REIMBURSEMENT
Key Development AstraZeneca and Daiichi Sankyo are reportedly close to reaching a pricing agreement with the United Kingdom's National Institute... Read more
600 DEAD, A FOURTH PROVINCE: THE BUNDIBUGYO STRAIN IS TESTING CONGO’S RESPONSE
Key Development The Democratic Republic of Congo (DRC) has confirmed a suspected Ebola case in Tshopo Province, extending the country's... Read more
KAILERA’S ORAL GLP-1 BREAKTHROUGH: THE NEXT CHAPTER OF THE GLOBAL OBESITY DRUG RACE
Key Development The global obesity drug market is entering a new phase as Kailera Therapeutics’ oral GLP-1 candidate HRS-7535 (KAI-7535)... Read more
Roche Raises the Bar in KRAS Lung Cancer, Intensifying the Race for Next-Generation Targeted Therapies
What This Means for the Future of Precision Oncology? Roche has announced positive topline results from the Phase III Krascendo-1... Read more
Upstream Biotech Capitalization: AstraZeneca Executes $1.77 Billion Strategic Licensing Deal with China’s CSPC to Capture Next-Gen Oligonucleotide Kidney Assets
Key Development Global biopharmaceutical aggregator AstraZeneca has formally entered into a definitive strategic collaboration and exclusive licensing agreement valued at... Read more
Expanding the Orphan Franchise: Sanofi’s Next-Gen Nexviazyme Secures Complete Phase III Efficacy to Supplant Myozyme in Infantile-Onset Pompe Disease
Key Development Global biopharmaceutical innovator Sanofi has officially released positive top-line data from its pivotal Phase III Baby-COMET clinical trial... Read more
Late-Stage Product Lifecycle Aggregation: Eli Lilly Divests Mainland China Commercial Rights for Blockbuster Verzenios to Innovent
Key Development Global biopharmaceutical leader Eli Lilly has formally executed a definitive strategic agreement transferring the mainland China commercialization rights... Read more









